drugset / Trial / NCT04537078

Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders

NCT04537078

RandomizedParallel-groupOpen-labelTreatment

Summary

The worldwide prevalence of primary and secondary infertility is estimated at \~2% and 10.5%, respectively, among women aged 20-44 years and attempting to conceive. Poor ovarian responders (PORs) involve 9-24% of patients undergoing in-vitro fertilization (IVF). proper tailoring of the ovarian stimulation protocol in order to maximize the number of oocytes collected represents a crucial step for them to eventually conceive. Recent evidence indicates that in the same menstrual cycle, there are multiple follicular recruitment waves. This coincides with the theory that folliculogenesis occurs in a wave-like fashion. Thus, within a single menstrual cycle, there can theoretically be multiple opportunities for a clinician to collect oocytes, as opposed to the conventional single cohort of antral follicles during the follicular phase. Utilizing this concept, clinicians have been attempting to retrieve oocytes from poor responders using both the follicular-phase stimulation (FPS) and the luteal-phase stimulation (LPS) protocols to increase the number of oocytes collected shorter within shorter period of time. By increasing the number of the retrieved oocytes collected, a better clinical can be assured since there is a clear relationship between the number of oocytes collected and live birth rates across all female age groups. which protocol is the most effective remains controversial and the efficacy of PPOS in POR compared with that of conventional protocols is unclear.

Timeline

Start
2020-09-01
Primary completion
2021-03-01
Completion
2021-09-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cetrorelix Other / unclassified
Comparator Decapeptyl Unknown 0.2 mg
Comparator Dydrogesterone Other / unclassified 20 mg
Comparator human chorionic gonadotropin Protein / enzyme biologic 10000 iu
Comparator Bravelle Unknown 225 iu
Comparator Bravelle Unknown 375 iu
Comparator Gonal-f Protein / enzyme biologic 225 iu
Comparator Gonal-f Protein / enzyme biologic 375 iu
Comparator Gynera Unknown 0.03 mg Oral
Comparator Gynera Unknown 0.075 mg Oral
Comparator Menogon Unknown 225 iu
Comparator Menogon Unknown 375 iu
Comparator Menopur Protein / enzyme biologic 225 iu
Comparator Menopur Protein / enzyme biologic 375 iu
Comparator Progesterone Other / unclassified 100 mg Intramuscular
Comparator Progesterone Other / unclassified 800 mg Intramuscular
Comparator estradiol valerate Unknown Oral

Indications